Liege, Belgium, 05 June 2020 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that following the signature of the capital commitment agreement with LDA Capital Limited announced on April 24, 2020, the Board of Directors approved on May 22, 2020 an increase to the Company’s capital by means of an issuance of new ordinary shares through authorized capital. The first put option notice was issued last Friday, May 29, 2020, according to the terms of the capital commitment agreement.